TY - JOUR
T1 - Drug-coated balloon in peripheral artery disease
AU - Shanmugasundaram, Madhan
AU - Murugapandian, Sangeetha
AU - Truong, Huu Tam
AU - Lotun, Kapildeo
AU - Banerjee, Subhash
N1 - Publisher Copyright:
© 2018
PY - 2019/4
Y1 - 2019/4
N2 - Peripheral artery disease (PAD) is highly prevalent but is often underdiagnosed and undertreated. Lower extremity PAD can often be life style limiting. Revascularization in carefully selected lower extremity PAD patients improves symptoms and functional status. Surgical revascularization used to be the only available strategy, but in the recent years, endovascular strategies have gained popularity due to faster recovery times with low morbidity and mortality rates. Endovascular procedures have increased significantly in the United States in the past few years. That being said, higher restenosis rates and low long-term patency rates have been the limiting factors for this strategy. Drug eluting stents have been introduced to help with lowering restenosis, however lower extremity PAD involves long segment where the outcomes of stents are suboptimal. Also, the disease often crosses joint line that makes it less ideal for the stents. Drug-coated balloons (DCB) have been introduced to improve patency rates following endovascular intervention for lower extremity PAD. They have gained popularity among endovascular specialists due to its ease of use and the concept of “leave nothing behind”. This is a review of scientific evidence supporting DCB use in PAD.
AB - Peripheral artery disease (PAD) is highly prevalent but is often underdiagnosed and undertreated. Lower extremity PAD can often be life style limiting. Revascularization in carefully selected lower extremity PAD patients improves symptoms and functional status. Surgical revascularization used to be the only available strategy, but in the recent years, endovascular strategies have gained popularity due to faster recovery times with low morbidity and mortality rates. Endovascular procedures have increased significantly in the United States in the past few years. That being said, higher restenosis rates and low long-term patency rates have been the limiting factors for this strategy. Drug eluting stents have been introduced to help with lowering restenosis, however lower extremity PAD involves long segment where the outcomes of stents are suboptimal. Also, the disease often crosses joint line that makes it less ideal for the stents. Drug-coated balloons (DCB) have been introduced to improve patency rates following endovascular intervention for lower extremity PAD. They have gained popularity among endovascular specialists due to its ease of use and the concept of “leave nothing behind”. This is a review of scientific evidence supporting DCB use in PAD.
KW - Drug-coated balloon
KW - Endovascular interventions
KW - Peripheral artery disease
UR - http://www.scopus.com/inward/record.url?scp=85046813241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046813241&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2018.04.017
DO - 10.1016/j.carrev.2018.04.017
M3 - Review article
C2 - 29730237
AN - SCOPUS:85046813241
SN - 1553-8389
VL - 20
SP - 338
EP - 343
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
IS - 4
ER -